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Background: Mitral regurgitation (MR) after myocardial infarction (MI) is a powerful predictor of increased morbidity and mortality. The 
relationship between MR, medical costs, and quality of life (QOL) post-MI has not been well described.
Methods: In this multinational clinical trial of patients with MI complicated by heart failure and/or left ventricular systolic dysfunction, site 
investigators reported the presence and severity of MR at enrollment (mean 4.9 days post MI). We collected data on interval resource use (inpatient 
care, outpatient visits and procedures, emergency department visits, and medications) at each study visit for all patients and assigned country-
specific unit costs. We measured health-related QOL in a subset of patients at 6-month intervals using a standardized measure (EQ-5D) for health 
preference.
Results: Of 9638 patients with MR data and resource use follow-up, 1780 (18.5%) had moderate or severe MR. Compared to patients with 
no or mild MR, these patients had higher annual rates of outpatient visits (11.0 vs 9.6, p<0.0001), emergency department visits (0.32 vs 0.25, 
p<0.0001), subsequent hospitalizations (0.72 vs 0.56, p<0.0001), and inpatient days (8.3 vs 5.0, p<0.0001), but lower rates of cardiac tests 
and procedures (0.45 vs 0.55, p<0.0001). Mean annual costs were significantly higher in those with moderate or severe MR ($8378 vs $6922; 
difference $1456, 95% CI $856 to $2086) due to significantly higher inpatient care costs ($6717 vs $5202; difference $1515, 95% CI $969 
to $2106). 3054 patients with MR data were included in the QOL substudy. Among surviving patients at each interval, those with moderate or 
severe MR had significantly lower QOL at baseline (by EQ-5D preference weight: 71.1 vs 77.6, p<0.0001) and more rapid decline in QOL over time 
(absolute change over 24 months; -13.7 vs -8.2, p=0.0025).
Conclusion: In contemporary survivors of high-risk MI, patients with moderate or severe MR have higher subsequent medical costs, largely driven 
by increased inpatient care, and progressively worse QOL relative to patients with no or mild MR. Therapies aimed at treating post-MI MR could 
potentially improve QOL and decrease costs, and should be further evaluated.
